Expression of Ki-67, Bcl-2, survivin and p53 proteins in patients with pulmonary carcinoma

Advances in Experimental Medicine and Biology

Volumn 756, Issue , 2013, Pages 15-21

  Halasova, E ^a   Adamkov, M ^a   Matakova, T ^a   Vybohova, D ^a   Antosova, M ^a   Janickova, M ^a   Singliar, A ^b   Dobrota, D ^a   Jakusova, V ^a  

^a University Teaching Hospital in Martin   (Slovakia)

^b Department of Pathology   (Slovakia)

Author keywords

Bcl 2 protein; Immuno histo chemistry; Ki 67 protein; Lung cancer; P53 protein; Survivin

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; SURVIVIN;

CANCER MORPHOLOGY; CANCER PROGNOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION;

EID: 84867520752     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-4549-0_3     Document Type: Conference Paper

References (34)

1. Akyürek, N., Memi?, L., Ekinci, O., Köktürk, N., & Oztürk, C. (2006). Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Archiv, 449 (2), 164-170.
2. Altieri, D. C. (2003). Validating survivin as a cancer therapeutic target. Nature Reviews. Cancer, 3 , 46-54.
3. Borner, Ch. (1996). Diminished cell proliferation associated with the deathprotective activity of Bcl-2. Journal of Biological Chemistry, 271 (22), 12695-12698.
4. Coutts, A. S., & Thangue, N. (2006). The p53 response during DNA damage: Impact of transcriptional cofactors. Biochemical Society Symposium, 73 , 181-189.
5. Deng, Y., & Wu, X. (2000). Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proceedings of the National Academy of Sciences of the USA, 97 , 12050-12055.
6. Fan, J., Wang, L., Jiang, G. N., He, W. X., & Ding, J. A. (2008). The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer, 61 , 91-96.
7. Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer, 46 (4), 765-781.
8. Han, B., Lin, S., Yu, L. J., Wang, R. Z., & Wang, Y. Y. (2009). Correlation of 18F-FDG PET activity with expressions of survivin, Ki-67, and CD34 in non-small-cell lung cancer. Nuclear Medicine Communications, 30 (11), 831-837.
9. Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H., & Tateishi, R. (1995). High prevalence of Bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Research, 15 (2), 503-505.
10. Isobe, M., Emanuel, B. S., Givol, D., Oren, M., & Croce, C. M. (1986). Localization of gene for human p53 tumor antigen to band 17p13. Nature, 320 (6057), 84-85.
11. Jiang, S. X., Sato, Y., Kuwao, S., & Kameya, T. (1995). Expression of Bcl-2 oncogene protein is prevalent in small cell lung carcinomas. The Journal of Pathology, 177 (2), 135-138.
12. Jin, H. O., Yoon, S. I., Seo, S. K., Lee, H. C., Woo, S. H., Yoo, D. H., Lee, S. J., Choe, T. B., An, S., Kwon, T. J., Kim, J. I., Park, M. J., Hong, S. I., Park, I. C., & Rhee, C. H. (2006). Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochemical Pharmacology, 72 (10), 1228-1236.
13. Jinz, Z., & El-Deiry, W. S. (2005). Overview of cell death signaling pathways. Cancer Biology & Therapy, 4 , 139-163.
14. Kawasaki, H., Altieri, D. C., Lu, C. D., Toyoda, M., Tenjo, T., & Tanigawa, N. (1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Research, 58 , 179-185.
15. Kitada, S., Takayama, S., De Riel, K., Tanaka, S., & Reed, J. C. (1994). Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of Bcl-2 gene expression. Antisense Research and Development, 4 (2), 71-79.
16. Krug, L. M., Kris, M. G., Rosenzweig, K., & Travis, W. D. (2008). Cancer of the lung. In V. T. DeVita Jr., S. Hellman, & S. A. Rosenberg (Eds.), Cancer: Principles & practice of oncology (8th ed., pp. 947-966). Philadelphia: Lippincott Williams Wilkins.
17. Matlashewski, G., Lamb, P., Pim, D., Peacock, J., Crawford, L., & Benchimol, S. (1984). Isolation and characterization of a human p53 cDNA clone: Expression of the human p53 gene. EMBO Journal, 3 (13), 3257-3262.
18. Mirza, A., McGuirk, M., Hockenberry, T. N., Wu, Q., Ashar, H., Black, S., Wen, S. F., Wang, L., Kirschmeier, P., Bishop, W. R., Nielsen, L. L., Pickett, C. B., & Liu, S. (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 21 , 2613-2622.
19. Mitsudomi, T., Hamajima, N., Ogawa, M., & Takahashi, T. (2000). Prognostic signi fi cance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clinical Cancer Research, 6 , 4055-4063.
20. Moll, U. M., & Zaika, A. (2001). Nuclear and mitochondrial apoptotic pathways of p53. FEBS Letters, 493 , 65-69.
21. Nakano, J., Huang, C. L., Liu, D., Ueno, M., Sumitomo, S., & Yokomise, H. (2005). Survivin gene expression is negatively regulated by p53 tumor suppressor gene in non-small cell lung cancer. International Journal of Oncology, 27 (5), 1215-1221.
22. Pietenpol, J. A., & Stewardt, Z. A. (2002). Cell cycle checkpoint signaling: Cell cycle arrest versus apoptosis. Toxicology, 181 , 475-481.
23. Pluquet, O., & Hainaut, P. (2001). Genotoxic and non-genotoxic pathways of p53 induction. Cancer Letters, 174 , 1-15.
24. Schmitt, C. A., Rosenthal, C. T., & Lowe, S. W. (2000). Genetic analysis of chemoresistance in primary murine lymphomas. Nature Medicine, 6 (9), 1029-1035.
25. Schuler, M., & Green, D. (2001). Mechanisms of p53-dependent apoptosis. Biochemical Society Transactions, 29 , 36-42.
26. Shert, T., Dy, G. K., & Adjei, A. (2008). Small cell lung cancer. Mayo Clinic Proceedings, 83 (3), 355-367.
27. Skov, B. G., Holm, B., Erreboe, A., Skov, T., & Mellemgaard, A. (2010). ERCC1 and Ki-67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: Distribution and impact on survival. Journal of Thoracic Oncology, 5 (4), 453-459.
28. Soomro, I. N., Holmes, J., & Whimster, W. F. (1998). Predicting prognosis in lung cancer: Use of proliferation marker, Ki-67 monoclonal antibody. The Journal of the Pakistan Medical Association, 48 (3), 66-69.
29. Tsao, A., & Glisson, B. (2006). Small cell lung cancer. In H. Kantarjian, R. Wolff, & C. Koller (Eds.), Anderson manual of medical oncology (pp. 233-256). New York: McGraw-Hill.
30. Velculescu, V. E., Madden, S. L., Zhang, L., Lash, A. E., Yu, J., Rago, C., Lal, A., Wang, C. J., Beaudry, G. A., Ciriello, K. M., Cook, B. P., Dufault, M. R., Ferguson, A. T., Gao, Y., He, T. C., Hermeking, H., Hiraldo, S. K., Hwang, P. M., Lopez, M. A., Luderer, H. F., Mathews, B., Petroziello, J. M., Polyak, K., Zawel, L., & Kinzler, K. W. (1999). Analysis of human transcriptomes. Nature Genetics, 32 , 387-388.
31. Wistuba, L., Gadzar, A. F., & Minna, J. D. (2001). Molecular genetics of small cell lung carcinoma. Seminars in Oncology, 28 (Suppl 4), 3-13.
32. Yamashita, S., Masuda, Y., Kurizaki, T., Haga, Y., Murayama, T., Ikei, S., Kamei, M., Takeno, S., & Kawahara, K. (2007). Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Research, 27 , 2803-2808.
33. Yamashita, S., Chujo, M., Miyawaki, M., Tokuishi, K., Anami, K., Yamamoto, S., & Kawahar, K. (2009). Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research, 28 (1), 22.
34. Yu, J., & Zhang, L. (2005). The transcriptional targets of p53 in apoptosis control. Biochemical and Biophysical Research Communications, 331 , 851-858.